Compass Therapeutics Q1 EPS $(0.08) Beats $(0.11) Estimate
Portfolio Pulse from Benzinga Newsdesk
Compass Therapeutics (NASDAQ:CMPX) reported Q1 losses of $(0.08) per share, surpassing the analyst consensus estimate of $(0.11) by 27.27%. This represents a 33.33% increase in losses compared to $(0.06) per share from the same period last year.
May 13, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Compass Therapeutics reported better-than-expected Q1 earnings, with a smaller loss per share than analysts anticipated, indicating a potential positive outlook despite an increase in losses year-over-year.
Beating earnings estimates typically generates positive investor sentiment, potentially leading to a short-term increase in stock price. However, the increase in losses year-over-year could temper some of the optimism.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100